Inflammatory Bowel Disease

Dubinsky describes the evolution from anti-TNF therapies to IL-23 antagonists and the significance of mirikizumab’s approval for Crohn’s disease.

The approval is based on data from the phase 3 VIVID-1 study and marks mirikizumab’s second approval in IBD, the first being ulcerative colitis in 2023.

Positive phase 2b data show duvakitug met primary endpoints for clinical remission in ulcerative colitis and endoscopic response in Crohn disease.

The supplemental Biologics License Application is supported by the phase 3 ASTRO study of guselkumab SC induction therapy in ulcerative colitis.

HCPLive spoke with Kastl at NASPGHAN about the team’s study on the immune response to the COVID-19 vaccination among children with IBD.

At NASPGHAN, HCPLive spoke to Hamant about her team’s study that showed their algorithm was linked to increased VTE Prophylaxis among Pediatric IBD.

At NASPGHAN 2024, Collen told HCPLive the promising early data of advanced combination therapy for pediatric refractory IBD although hurdles exist.

HCPLive spoke to Collen at NASPGHAN 2024 about early research on environmental exposures prevalent in children with Crohn’s Disease.

At NASPGHAN 2024, HCPLive spoke to Shameem about his study on inpatient outcomes of pediatric patients with IBD and GAD vs patients without GAD.

A retrospective review of a community-based practice provides insights into navigating setbacks in IBD care initiation due to insurance requirements.

Sands reviews long-term phase 3 data from the LUCENT-3 and VIVID-2 extension studies of mirikizumab in UC and CD presented at ACG 2024.

Axelrad reviews preliminary findings from a study assessing the utility of a new monitoring technology for improving IBD medication adherence and outcomes.

New ACG 2024 data show patients with both IBD and vitamin D deficiency face longer, more expensive hospital stays, as well as risk of colectomy.

Banty discusses recent advancements in the ulcerative colitis and Crohn disease treatment landscapes, explaining how to navigate the growing number of treatment options.

Solomon explains how to navigate the growing Crohn disease treatment armamentarium and the importance of treatment positioning.

The decision is based on rates of clinical and endoscopic remission with guselkumab in the ongoing phase 2b/3 QUASAR study.

The HCPLive August gastroenterology month in review spotlights expansions in gastrointestinal treatment and screening access as well as the newest edition of Qazi Corner.

AHN Division of Gastroenterology, Hepatology, and Nutrition addresses patients’ challenging symptoms and needs with wide-ranging strategies and innovative treatments.

Silvio Danese, MD, PhD; Bruce Sands, MD, and Jean-Frederic Colombel, MD, conclude by sharing their approaches to evaluating patient satisfaction and expectations when providing care for ulcerative colitis and Crohn's disease, while also touching upon the importance of discussing the potential need for escalating or switching therapies to better manage the underlying disease processes.

Jean-Frederic Colombel, MD, examines considerations for transitioning patients from intravenous to subcutaneous infliximab and evaluates the role of subcutaneous infliximab within the evolving landscape of inflammatory bowel disease treatments.

A key opinion leader analyzes the clinical remission and endoscopic response data from the LIBERTY CD and LIBERTY UC trials for subcutaneous infliximab-dyyb injection, contrasts it with intravenous infliximab, and evaluates the drug's safety and efficacy profile.

Jean-Frederic Colombel, MD, offers insights into subcutaneous infliximab-dyyb injection, detailing its administration and approved indications for ulcerative colitis and Crohn's disease.

Medical experts in inflammatory bowel disease discuss the current evidence on dual advanced therapy for ulcerative colitis and Crohn's disease, highlighting the potential benefits, while also addressing the challenges and complexity of treatment management.

Gastroenterologist experts discuss the current landscape of biologic treatments for inflammatory bowel disease and the occasional necessity to switch between different biologic agents, while also sharing insights on their preferred treatment sequencing strategies.

The July 2024 gastroenterology month in review highlights FDA news, GI pipeline updates, and a new clinical practice update from the American Gastroenterological Assocation.